Information for continuing education (CE) credit

COVID-19 Investigational Therapies and Pharmacogenetics

Activity date: October 27, 2020

Course director: Gretchen Brummel, PharmD, BCPS

Vizient is committed to complying with the criteria set forth by the accrediting agencies in order to provide this quality course. To receive credit for educational activities, you must successfully complete all course requirements.

**Requirements**

1. Attend the course in its entirety
2. After the course, you will receive an email with instructions and an access code that you will need to obtain your CE credit
3. **Complete the process no later than December 10, 2020**

Upon successful completion of the course requirements, you will be able to print your CE certificate and/or statement of credit for pharmacy education.

**Important note for pharmacists and pharmacy technicians**

All credit awarded to pharmacists must be via CPE Monitor; paper certificates are not valid for submission.  Pharmacists will be able to print individual statements of credit and their transcripts from their NABP e-profile created at [www.mycpemonitor.net](http://www.mycpemonitor.net) or [www.nabp.net](http://www.nabp.net).

1. Please provide an accurate **NABP ID number** and **date of birth** (**mm/dd** – do not include birth year)
2. Vizient will upload your **NABP ID number** and **date of birth** into CPE Monitor within 24 hours after the completion of all steps required to receive credit.

If your **NABP ID number** and/or **date of birth** are returned as invalid after the upload, Vizient will make one attempt to contact you for corrections within a 45-day window. After the 45-day window expires, Vizient will not accept the information, and Vizient will not be able to process your CE credit.

**Pharmacist learning objectives**

1. Investigate the role of G6PD deficiency with hydroxychloroquine and chloroquine use
2. Identify the related supportive therapies for SARS-CoV-2

**Pharmacy technician learning objectives**

1. Review investigational therapies for SARS-CoV-2 and their relation to pharmacogenetics



**Joint Accreditation Statement:**

In support of improving patient care, Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Designation Statements:**

#### PHARMACY

Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.

Universal Activity Number: JA0006103-0000-20-188-L01-P

Universal Activity Number: JA0006103-0000-20-188-L01-T

### CEU

Vizient, Inc. will award CEUs to each participant who successfully completes this program. The CEU is a nationally recognized unit of measure for continuing education and training programs that meet certain criteria (1 contact hour = 0.1 CEU).

**CONFLICT OF INTEREST/CONTENT VALIDATION POLICY:**

As an accredited provider of continuing medical education/continuing education Vizient is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. Vizient requires all potential faculty and program planners, in advance, to disclose financial relationships with relevant commercial interests. Vizient uses that information to determine whether prospective contributors have potential conflicts of interest. If significant relationships are disclosed, Vizient assesses how those potential conflicts of interest may affect CME/CE content. Vizient requires that all conflicts of interest be resolved prior to participation in the activity. Vizient is committed to resolving potential conflicts of interest, although if contributors have significant relationships that cannot be reconciled, Vizient reserves the right to prohibit participation. Faculty presenters are also expected to disclose any discussion of (1) off-label or investigational uses of FDA approved commercial products or devices or (2) products or devices not yet approved in the United States.

DISCLOSURE STATEMENTS:

### Current accrediting agency guidelines and Vizient policy state that participants in educational activities should be made aware of any affiliation or financial interest that may affect the presentation and if there will be any discussion of unapproved or investigative use of commercial products/devices. Each planning committee member, reviewer and presenter has completed a Disclosure of Relevant Financial Relationships form.

Relevant financial relationships: Planning committee members and presenters have nothing to disclose

### Planning committee members

**Gretchen Brummel, PharmD, BCPS**

Consulting Director, Pharmacy

Vizient

**Jackie Stokes, BS**

Manager, Pharmacy Program

Vizient

### Course reviewer

**Gretchen Brummel, PharmD, BCPS**

Consulting Director, Pharmacy

Vizient

### Presenter

**Amanda Elchynski, PharmD, BCPS**

Clinical Pharmacogenetics Fellow

Center for Pharmacogenetics and Precision Medicine

Department of Pharmacology and Translational Research

University of Florida | College of Pharmacy